Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL99907 | 0.96 | KMT2A (0.49) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL1021859 | 0.87 | — | — | |
| SCHEMBL2441984 | 0.80 | MEN1 (0.40) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL10248266 | 0.79 | KMT2A (0.42) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL10973800 | 0.79 | MAPT (0.41) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL10908592 | 0.77 | MEN1 (0.38) | MEN1KMT2AMAPTLMNA | |
| SCHEMBL31680983 | 0.76 | FKBP5 (0.36) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL16321161 | 0.75 | MAPT (0.44) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL3103319 | 0.73 | PARP1 (0.38) | MEN1KMT2ALMNARXFP1 | |
| SCHEMBL125003 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276979-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-09-04 | — | — | US | disclosed |
| US-9394279-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-07-19 | — | — | US | disclosed |
| EP-2651885-A1 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20120172290-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2012083170-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20050065349-A1 | Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems | BUCHWALD STEPHEN L (US) | 2005-03-24 | — | — | US | disclosed |
| US-6787655-B2 | TRANSITION-METAL-CATALYZED ASYMMETRIC 1,4-ADDITION OF A NUCLEOPHILE, E.G., HYDRIDE, TO CYCLIC AND ACYCLIC ENOATES AND ENONES AND THE CATALYST CONTAINING A COPPER AND AN ASYMMETRIC BIDENTATE BISPHOSPHINE LIGAND | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2004-09-07 | — | — | US | disclosed |
| US-20030125563-A1 | Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-03 | — | — | US | disclosed |
| US-6465664-B1 | CATALYZED WITH A TRANSITION METAL CATALYST COMPOSED OF A COPPER COMPOUND AND AN ASYMMETRIC LIGAND, SUCH AS A PHOSPHINE, A NUCLEOPHILE AND A BASE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2002-10-15 | — | — | US | disclosed |
| US-6423714-B2 | FOR EXAMPLE, 3-BENZYL-3-TRICHLOROACETAMIDO-1-(N-PHENYLAMINO-CARBONYL)-N-(3-(2 -MORPHOLINOETHOXY)-PHENYL)AMINO)METHYLCYCLO-HEXENE; IRRITABLE BOWEL MOVEMENT; ESOPHAGEAL REFLUX; COUNTER-ACTING ERYTROMYCIN SIDE EFFECTS | ORTHO MCNEIL-PHARMACEUTICAL, INC.. | 2002-07-23 | — | — | US | disclosed |
| US-20020002192-A1 | Novel cyclohexene derivatives useful as antagonists of the motilin receptor | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-03 | — | — | US | disclosed |
| WO-2001068621-A1 | NOVEL CYCLOHEXENE DERIVATIVES USEFUL AS ANTAGONISTS OF THE MOTILIN RECEPTOR | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001019761-A2 | ASYMMETRIC 1,4-REDUCTIONS OF AND 1,4-ADDITIONS TO ENOATES AND RELATED SYSTEMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-03-22 | — | — | WO | disclosed |
| US-4921994-A | ANALGESICS, ANTIEMETICS | PFIZER INC. (US) | 1990-05-01 | — | — | US | disclosed |
| US-4831059-A | ANTIEMETICS; DIARRHEA; CENTRAL NERVOUS SYSTEM | PFIZER INC. (US) | 1989-05-16 | — | — | US | disclosed |
| US-4371720-A | ANTIDIARRHEALS, ANTIEMETICS | PFIZER INC. (US) | 1983-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065349-A1 | Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems | APEX1, AP2A1, ENPP1 | MEN1 66/4885KMT2A 1444/4885MAPT 4799/4885 |
| US-20020002192-A1 | Novel cyclohexene derivatives useful as antagonists of the motilin receptor | MLNR, GIPR, MUSK | MEN1 1790/4885KMT2A 4641/4885MAPT 4348/4885 |
| US-20250276979-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | MEN1 3914/4885KMT2A 3085/4885MAPT 2197/4885 |
| US-20030125563-A1 | Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems | APEX1, AP2A1, ENPP1 | MEN1 66/4885KMT2A 1444/4885MAPT 4799/4885 |
| US-20120172290-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | MEN1 4681/4885KMT2A 4093/4885MAPT 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.